Overexpression of SLC38A2 leads to complete resistance to anti-estrogen therapy and is induced in tamoxifen resistance, contributing to endocrine resistance in breast cancer (Morotti et al., 2019). The gene discussed is SLC38A2; the disease is breast carcinoma.